INDP News and Press, Indaptus Therapeutics Inc. From 05/19/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indaptus Therapeutics (NASDAQ: INDP ) got an update from the FDA. This allows it to move forward with a Phase 1 clinical trial. That trial is for Decoy20, which is designed to treat cancer tumors. Source: Bu...

Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceu...

Indaptus Therapeutics (INDP) +22% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors. Zealand Pharma (ZEAL) +19% announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism.  CBAK Energy Technology (CBAT)&#...

Indaptus Therapeutics (NASDAQ:INDP) said the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to begin a phase 1 trial of Decoy20 to treat patients with advanced solid tumors when currently approved therapies have failed. The company pla...

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical tri...

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference on W...

Indaptus Therapeutics press release (NASDAQ:INDP): Q1 GAAP EPS of -$0.41. Cash and cash equivalents of $33.21M For further details see: Indaptus Therapeutics GAAP EPS of -$0.41

Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("...

NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 2 nd Annual Chronic HBV Drug Development Summit taking pl...

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference made...